Type 2 Diabetes and the Glucagon Renaissance: Restoring Bihormonal Equilibrium

Documenti analoghi

• Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral Nutrients in Type 2 Diabetes
  di: Zhenxi Wang, et al.
  Pubblicazione: (2026)
• Low‐Dose Glucagon After Fasted Morning Exercise in People With Type 1 Diabetes—A Randomised Crossover Comparison of Low and High Carbohydrate Diets
  di: Signe Schmidt, et al.
  Pubblicazione: (2026)
• Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes
  di: Zhimin Xu, et al.
  Pubblicazione: (2024)
• Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study
  di: Takeshi Miyatsuka, et al.
  Pubblicazione: (2026)
• Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
  di: Jonathan Brix Winther, et al.
  Pubblicazione: (2024)